The Portuguese version of the Personal and Social Performance Scale (PSP): reliability, validity, and relationship with cognitive measures in hospitalized and community schizophrenia patients

IntroductionDeficits in social functioning are a core feature of schizophrenia and are influenced by both symptomatic and neurocognitive variables.ObjectivesIn the present study we aimed to determine the reliability and validity of the Portuguese version of the Personal and Social Performance (PSP) scale, and possible correlations with measures of cognitive functioning.MethodsOne-hundred and four community and inpatients with schizophrenia were assessed using measures of social functioning and symptom severity alongside measures of executive function, processing speed and verbal memory.ResultsThe reliability of the PSP was found to be satisfactory, with a Cronbach's alpha coefficient of 0.789. Inter-rater reliability in the four domains of the PSP varied from 0.430 to 0.954. Low-functioning patients (PSP < 70) were older, had longer duration of illness, were more symptomatic and had worse cognitive performances, as compared to high-functioning patients (PSP ≥ 70). In a regression model, deficits in social functioning were strongly predicted both by symptomatic and neurocognitive variables; these together accounted for up to 62% of the variance.ConclusionsThe present study supports the reliability and validity of the Portuguese language version of the PSP and further supports the original measure. The co-administration of brief cognitive assessments with measures of functioning may lead to more focused interventions, possibly improving outcomes in this group.

Download Full-text

Palmitate de palipéridone chez des patients atteints de schizophrénie, non-aigus mais symptomatiques, après échec d’un traitement par aripiprazole

European Psychiatry ◽

10.1016/j.eurpsy.2014.09.039 ◽

2014 ◽

Vol 29 (S3) ◽

pp. 658-658

Author(s):

P. Bergmansl ◽

L. Hargarter ◽

P. Cherubin ◽

E. Rancans ◽

Y. Bez ◽

...

Keyword(s):

Oral Dose ◽

Rating Scale ◽

Extrapyramidal Symptom ◽

Social Performance ◽

La Substitution ◽

Symptom Rating ◽

Performance Scale

ObjectifsÉvaluer la tolérance, la sécurité d’emploi et la réponse à un traitement par le palmitate de palipéridone (PP) administré en doses mensuelles flexibles dans un sous-groupe de patients adultes atteints de schizophrénie, non-aigus mais symptomatiques, après échec d’un traitement par aripiprazole oral.MéthodesÉtude internationale multicentrique, ouverte, prospective de 6 mois.Paramètres d’évaluationChangement du score total de PANSS, de CGI-S et CGI-C, du fonctionnement personnel et social (Personal and Social Performance Scale [PSP]), des symptômes extrapyramidaux (Extrapyramidal Symptom Rating Scale [ESRS]) et événements indésirables (EIs).RésultatsQuarante-six patients (73,9 % d’hommes, âge moyen 34,4 ± 9,4 ans, 78,3 % souffrant de schizophrénie paranoïde) ont été étudiés. La principale raison de la substitution d’aripiprazole oral (dose moyenne de 22,7 ± 10,7 mg/jour) par le PP était « le choix du patient » (39,1 %) ; 67,4 % des patients ont terminé l’étude à 6 mois. Le score total moyen de PANSS a diminué de 74,7 ± 14,9 à l’inclusion à 62,6 ± 16,5 lors de la dernière observation (soit une variation moyenne de −12,2 ± 16,7 points ; IC 95 % [−17,1 ; −7,2] ; p < 0,0001). Chez 52,2 % des patients, l’amélioration du score total de PANSS a été ≥ 20 % ; le pourcentage de patients considérés légèrement malades ou moins selon les critères de la CGI-S est passé de 23,9 % à 56,5 %. Au total, 75,5 % des patients ont été jugés améliorés à la CGI-C par rapport au traitement antérieur par aripiprazole. Le score de l’échelle de fonctionnement PSP s’est amélioré de 58,9 ± 13,4 à 62,9 ± 15,2 (p = 0,041). Les EIs touchant ≥ 5 % des patients étaient : anxiété (n = 6), douleur au site d’injection, bronchite, insomnie, akathisie (n = 4 chacun) et augmentation du poids, dépression et douleur aux extrémités (n = 3 chacun). Les symptômes extrapyramidaux selon ESRS se sont améliorés de façon significative depuis l’inclusion jusqu’à 6 mois chez les patients ayant terminé l’étude (−1,4 ± 2,7 ; p < 0,006).ConclusionsL’utilisation de doses flexibles de PP a permis une amélioration symptomatologique et fonctionnelle cliniquement significative chez des patients atteints de schizophrénie, non-aigus et en échec de traitement par aripiprazole oral. Le PP a été bien toléré avec une diminution des symptômes extrapyramidaux.

Download Full-text

Sex Differences in Severity, Social Functioning, Adherence to Treatment, and Cognition of Adolescents with Schizophrenia

Schizophrenia Research and Treatment ◽

10.1155/2016/1928747 ◽

2016 ◽

Vol 2016 ◽

pp. 1-7 ◽

Cited By ~ 3

Author(s):

Rodolfo Pérez-Garza ◽

Gamaliel Victoria-Figueroa ◽

Rosa Elena Ulloa-Flores

Keyword(s):

Sex Differences ◽

Social Functioning ◽

Negative Symptoms ◽

Clinical Presentation ◽

Social Performance ◽

Adherence To Treatment ◽

Cognitive Improvement ◽

Dsm Iv ◽

Performance Scale ◽

Positive And Negative Symptoms

Background.Previous studies have reported sex differences in the clinical presentation and outcome of adult patients with schizophrenia; the aim of present study was to compare the clinical characteristics, social functioning, adherence to treatment, and cognition of adolescents with this diagnosis in a six-month followup.Methods.A total of 87 adolescents with a DSM-IV diagnosis of schizophrenia or schizophreniform disorder were evaluated with the Positive and Negative Symptoms Scale (PANSS), the Matrics Consensus Cognitive Battery (MCCB), Personal and Social Performance Scale (PSP), and the Rating of Medication Influences (ROMI).Results.Both groups showed a similar improvement in all PANSS factors and in the PSP scores during the followup. Males better adhered to treatment. Females displayed better results in the area of social cognition (F=6.3, df = 2,52, andp=0.003) and attention/vigilance (F=8.3, df = 2,51, andp=0.001).Conclusions.Male and female adolescents showed similar clinical presentation and functioning but a different pattern of cognitive improvement and adherence to treatment. This trial is registered with Clinicaltrials.govII3/02/0811.‏

Download Full-text

Social Cognition and Psychosocial Functioning in Schizophrenia

European Psychiatry ◽

10.1016/s0924-9338(09)70529-2 ◽

2009 ◽

Vol 24 (S1) ◽

pp. 1-1

Author(s):

G. Juckel ◽

M. Brüne

Keyword(s):

Social Cognition ◽

Theory Of Mind ◽

Psychosocial Functioning ◽

Social Performance ◽

Anterior Cingulate ◽

Healthy Controls ◽

Significant Difference ◽

Close Relationship ◽

Functioning Level ◽

Performance Scale

Ability for empathy and theory of mind are diminshed in patients with schizophrenia. These kinds of social cognition are, however, necessary to interact with other people and obtain a well-balanced psychosocial functioning level, i.e. to have friends, to go for work, to be in partnership and so on. Own studies revealed that disturbances in social cognition are accompanied by fMRI activation deficits in distinct regions of the underlying neuronanatomical loop in schizophrenia. The most significant difference compared to healthy controls was found in the region of the anterior cingulate cortex (ACC) and medial prefrontal cortex (mPFC). We think that training of social cognition would improve both the neurobiological hypoactivation and the ability for empathy and theory of mind. As consequence, psychosocial functioning of the patients should be become better as measured e.g. by the personal and social performance scale (PSP). To emphazise the close relationship between social cognition, ist underlying neuobiology and psychosocial functioning is the main purpose of this lecture.

Download Full-text

Minimal detectable change of the Personal and Social Performance scale in individuals with schizophrenia

Psychiatry Research ◽

10.1016/j.psychres.2016.10.058 ◽

2016 ◽

Vol 246 ◽

pp. 725-729 ◽

Cited By ~ 3

Author(s):

Shu-Chun Lee ◽

Shih-Fen Tang ◽

Wen-Shian Lu ◽

Sheau-Ling Huang ◽

Nai-Yu Deng ◽

...

Keyword(s):

Social Performance ◽

Minimal Detectable Change ◽

Detectable Change ◽

Performance Scale

Download Full-text

Efficacy and safety of brexpiprazole in patients with schizophrenia presenting with severe symptoms: Post-hoc analysis of short- and long-term studies

Journal of Psychopharmacology ◽

10.1177/0269881120936485 ◽

2020 ◽

Vol 34 (8) ◽

pp. 829-838

Author(s):

Nicole Meade ◽

Lily Shi ◽

Stine R Meehan ◽

Catherine Weiss ◽

Zahinoor Ismail

Keyword(s):

Least Squares ◽

Social Performance ◽

Mean Difference ◽

Syndrome Scale ◽

Scale Total Score ◽

Short And Long Term ◽

Negative Syndrome ◽

Performance Scale ◽

Long Term Studies

Background: The treatment of patients with severe schizophrenia symptoms can be complicated and expensive. Aims: The purpose of this study was to evaluate the short- and long-term effects of brexpiprazole in patients with schizophrenia presenting with severe symptoms. Methods: Data were pooled from three six-week, randomized, double-blind, placebo-controlled studies and two 52-week, open-label extension studies. In the short-term studies, 1405 patients received placebo or brexpiprazole 2–4 mg/day; 412 brexpiprazole-treated patients rolled over into the long-term studies and received brexpiprazole 1–4 mg/day. More severe symptoms were defined as a Positive and Negative Syndrome Scale Total score >95 (median score at baseline). Outcomes included change in Positive and Negative Syndrome Scale Total and Personal and Social Performance scale scores. Results: Brexpiprazole improved Positive and Negative Syndrome Scale Total score over 6 weeks among more severely ill patients, with a least squares mean difference versus placebo of −6.76 (95% confidence limits: −9.80, −3.72; p<0.0001; Cohen’s d: 0.43). Brexpiprazole also improved Personal and Social Performance scale score over 6 weeks in more severely ill patients (least squares mean difference: 4.38; limits: 2.14, 6.62; p=0.0001; Cohen’s d: 0.38). Improvement of functioning was greatest in the ‘Self-care’ domain, followed by ‘Personal and social relationships’. Among less severely ill patients, brexpiprazole was superior to placebo on Positive and Negative Syndrome Scale Total and Personal and Social Performance scale at Week 6. Improvements were maintained over 58 weeks. No new safety or tolerability concerns were observed. Conclusions: Brexpiprazole is an efficacious and well-tolerated treatment for schizophrenia in patients with more severe, and less severe, symptoms.

Download Full-text

PSYCHOMETRIC PROPERTIES OF THE FRENCH VERSION OF THE PERSONAL AND SOCIAL PERFORMANCE SCALE (PSP) AMONG INDIVIDUALS WITH SCHIZOPHRENIA

Schizophrenia Research ◽

10.1016/j.schres.2010.02.470 ◽

2010 ◽

Vol 117 (2-3) ◽

pp. 285-286 ◽

Cited By ~ 1

Author(s):

Olivier Blanc ◽

Antonio Delgado ◽

Christophe Lancon ◽

Raymund Schwan ◽

Franck Schürhoff ◽

...

Keyword(s):

Psychometric Properties ◽

Social Performance ◽

French Version ◽

Performance Scale

Download Full-text

Validity and reliability of the Spanish version of the Personal and Social Performance scale in adolescents with schizophrenia

Schizophrenia Research ◽

10.1016/j.schres.2015.02.010 ◽

2015 ◽

Vol 164 (1-3) ◽

pp. 176-180 ◽

Cited By ~ 4

Author(s):

Rosa-Elena Ulloa ◽

Rogelio Apiquian ◽

Gamaliel Victoria ◽

Sofía Arce ◽

Natalia González ◽

...

Keyword(s):

Social Performance ◽

Spanish Version ◽

Validity And Reliability ◽

Performance Scale

Download Full-text

Validation of the Spanish Personal and Social Performance scale (PSP) in outpatients with stable and unstable schizophrenia

Revista de Psiquiatría y Salud Mental (English Edition) ◽

10.1016/s2173-5050(11)70003-6 ◽

2011 ◽

Vol 4 (1) ◽

pp. 9-18 ◽

Cited By ~ 2

Author(s):

María Paz Garcia-Portilla ◽

Pilar Alejandra Saiz ◽

Manuel Bousoño ◽

María Teresa Bascaran ◽

Carlos Guzmán-Quilo ◽

...

Keyword(s):

Social Performance ◽

Performance Scale

Download Full-text

Tratamento em regime compulsivo ambulatório: estudo de follow-up após um ano em Portugal

Revista Portuguesa de Psiquiatria e Saúde Mental ◽

10.51338/rppsm.2017.v1.i2.55 ◽

2017 ◽

pp. 21-9

Author(s):

Sofia Brissos ◽

Gonçalo Sobreira ◽

João Miguel Oliveira ◽

Zita Gameiro ◽

...

Keyword(s):

Mental Disorder ◽

Word Association ◽

Social Performance ◽

Digit Span ◽

Association Test ◽

Word Association Test ◽

Syndrome Scale ◽

Negative Syndrome ◽

Performance Scale

Enquadramento: Não existem evidências suficientes relativamente ao impacto do tratamento em regime compulsivo ambulatório (TCA). Objetivos: Avaliámos o impacto do TCA ao longo de um ano em sintomas, funcionamento pessoal e social, insight e cognição. Métodos: Análise naturalística, longitudinal, no início e no follow-up após um ano, de 15 pacientes seguidos numa consulta especializada de TCA. Os pacientes foram submetidos a avaliação estandardizada com o Positive and Negative Syndrome Scale (PANSS) (Escala Positiva e Negativa do Síndroma), Personal and Social Performance Scale (PSP) (Escala de Desempenho Pessoal e Social), Berrios-Markova Scale to Assess Unawareness in Mental Disorder (SUMD) (Escala de Avaliação da Falta de Consciência no Distúrbio Mental), Trails A e B, Digit Span, e o Controlled Oral Word Association Test (COWA) (Teste de Associação Verbal Controlada). Resultados: No follow-up houve melhorias significativas no funcionamento pessoal e social (PSP inicial total: média=46,9; follow-up: média=59,3), e nomeadamente nas atividades socialmente úteis incluindo trabalho e estudos (p=0,012) e relações pessoais e sociais (p=0,033). Três pacientes (20%) pontuaram =>69 no PSP, um bom nível de funcionamento. Porém, não verificámos melhorias significativas nos sintomas (PANSS=56,8), insight subjetivo ou objetivo (Berrios-Markova=10,0 e SUMD=11,0), ou desempenho cognitivo. Conclusões: No follow-up após um ano, os pacientes em TCA revelaram melhorias significativas no funcionamento pessoal e social, especificamente nas atividades socialmente úteis incluindo trabalho e estudos e nas relações pessoais e sociais, mas não registaram melhorias nos sintomas, insight e funcionamento cognitivo.

Download Full-text